Published On: Sat, Apr 24th, 2021

Caplin Point Laboratories gets FDA approval for Prochlorperazine Edisylate Injection

Tagged with: | | | | | | |

Caplin Point Laboratories said that its subsidiary has secured final approval from the (FDA) for its abbreviated new drug application (ANDA) for Prochlorperazine Edisylate Injection USP, 10 mg/2 mL (5 mg/mL) Vials presentations.

Prochlorperazine Edisylate Injection is a generic therapeutic equivalent version of (RLD), COMPAZINE Injection, manufactured by .

It is an antiemetic indicated for the control of severe nausea and vomiting.

Caplin Steriles, a subsidiary of Caplin Point Laboratories, gets FDA approval for Prochlorperazine Edisylate Injection

Caplin Steriles, a subsidiary of Caplin Point Laboratories, gets FDA approval for Prochlorperazine Edisylate Injection

– Chairman of Caplin Point Laboratories said: “We’re glad to receive 3 product approvals within a short period of time. All input materials for the launches have been secured and we’re working on the launch batches shortly.”

Related posts

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>